What ooo bionorica does

Bionorica SE is a German family-owned pharmaceutical company founded in 1933 by Joseph Popp in Nuremberg, now controlled by the second-generation owner Prof. Dr. Michael A. Popp. The company specializes in evidence-based phytopharmaceuticals (plant-based medicines) across three therapeutic areas: respiratory conditions (Sinupret, Sinupret extract, Bronchipret, Tonsilgon N, Tonsipret), urinary tract diseases (Canephron N), and gynecological disorders (Cyclodinon, Mastodinon, Klimadynon), with dronabinol as an adjacent cannabis-based offering for seriously ill patients. All products are developed under the proprietary Phytoneering concept — a vertically integrated process combining seed selection, cultivation, genetic plant identification, NIR-based field analysis, triple quadrupole and time-of-flight mass spectrometry, and clinical research — exclusively owned by Bionorica SE.

The company generates revenue primarily through OTC pharmacy sales of finished phytopharmaceutical products, with global OTC sales of EUR 272 million in 2017 and consolidated revenue exceeding EUR 300 million in 2018. A secondary B2B stream sells standardized plant extracts through wholly-owned subsidiaries Phytoneering Extracts Solutions GmbH (Neumarkt, Germany) and Phytoneering Extracts Solutions S.L. (Consell, Mallorca). Distribution combines pharmacy retail across 50+ countries with the proprietary Фитотека (Phytothek) science-educational pharmacy format (~1,000 units worldwide; 55 in Russia via Unipharm partnership; ~900 in Germany) and a 300+ medical representative field force covering 70+ Russian cities. The company is funded internally with a 79% equity ratio (2017) and reported EUR 14.9M of growth investment in 2017 alongside >EUR 100M of headquarters capex over five years.

Primary customers are healthcare professionals (physicians and pharmacists) who prescribe or recommend Bionorica products, and end-consumer patients seeking OTC plant-based alternatives for common conditions including rhinosinusitis, bronchitis, tonsillitis, cystitis, pyelonephritis, menstrual disorders, mastopathy, and menopausal symptoms. Bionorica is the No. 1 phytopharmaceutical manufacturer in Germany, market leader in several countries, and operates a global research network of 500+ universities, clinics, and institutes. OOO Bionorika is the wholly-owned Russian subsidiary (LLC, Moscow), part of Bionorica SE's group structure.

Name

ooo bionorica

Legal name

OOO Bionorika (ООО «Бионорика»)

Website

https://bionorica.ru

Company type

Private

Founded year

1933

Operating status

Operating

Short description

Bionorica SE is a German family-owned pharmaceutical company developing evidence-based plant-based (phytopharmaceutical) medicines for respiratory, urinary tract, and gynecological conditions. It sells OTC products such as Sinupret, Canephron, and Bronchipret through pharmacies in 50+ countries, with OOO Bionorika as its Russian subsidiary.

Ownership category

akta.pro rank

Product category

Phytopharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

akta.pro secondary industries

Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC), Cold, Flu & Cough Remedies (HLAIADAB), Sleep, Stress & Mood Support (HLAIADAG)

Keywords

• Phytopharmaceutical products
• Herbal medicinal products
• Plant-based pharmaceuticals
• Respiratory therapeutics
• Gynecological treatments

Headquarters

HQ city

Neumarkt

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Phytopharmaceutical Product Sales: Bionorica generates revenue primarily through the sale of its OTC (over-the-counter) and prescription plant-based pharmaceutical products. Global OTC sales in 2017 reached EUR 272 million. Revenue is distributed across three therapeutic segments: respiratory, urological, and gynecological. Russia and Germany are the strongest markets.
2. Dronabinol (Cannabis-based): Sales of dronabinol for improving quality of life of seriously ill patients. Global dronabinol sales in 2017 were approximately EUR 13.6 million, more than double the previous year, benefiting from German legislative changes allowing cannabis-based medication reimbursement.
3. Phytoneering Extracts (B2B): Phytoneering Extracts Solutions GmbH and S.L. produce and sell standardized plant extracts to other pharmaceutical manufacturers, generating revenue through ingredient supply agreements.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

OOO Bionorica is the Russian subsidiary of Bionorica SE, a German family-owned pharmaceutical company that develops, manufactures, and distributes evidence-based plant-based (phytopharmaceutical) medicines. Its product portfolio spans three therapeutic segments: respiratory tract treatments (Sinupret, Bronchipret, Tonsilgon N, Tonsipret), urinary tract treatments (Canephron N), and gynecological treatments (Cyclodinon, Mastodynon, Klimadynon). The company produces these medicines using its proprietary "Phytoneering" concept that combines plant cultivation, quality control, and clinical research, and sells them primarily as OTC products through pharmacies in Russia, Germany, and 50+ countries.

Product overview

Bionorica is a German pharmaceutical company specializing in evidence-based plant-based (phytopharmaceutical) medicines. The product portfolio consists of three main therapeutic areas: respiratory tract treatments (Синупрет®, Синупрет® экстракт, Бронхипрет®, Тонзилгон® Н, Тонзипрет®), urinary tract treatments (Канефрон® Н), and gynecological treatments (Циклодинон®, Мастодинон®, Климадинон®). All products are developed using the proprietary 'Phytoneering' concept, which combines traditional phytotherapy with modern pharmaceutical research and quality standards. The company positions itself as a leader in scientifically-backed herbal medicines, with products available in various forms including tablets, drops, syrups, and lozenges, targeting both adult and pediatric populations.

Differentiator

Problem solved

Functional benefit

Brands

• Phytoneering: Proprietary concept combining plant science and pharmaceutical engineering for developing plant-based medicines. Trademarked technology owned exclusively by Bionorica SE.

Products and services

• Sinupret® (Синупрет®)
• Sinupret® extract (Синупрет® экстракт)
• Bronchipret® (Бронхипрет®)
• Tonsilgon® N (Тонзилгон® Н)
• Tonsipret® (Тонзипрет®)
• Cyclodinon® (Циклодинон®)

Quantifiable outcome

• Global sales grew 17.6% in 2017 vs 2016
• +6 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• Unipharm (Юнифарма)coreChannel Partner/ Reseller/ Distributor · 14 September 2020Bionorica partnered with the Unipharm pharmacy chain to launch the 'Фитотека' (Phytothek) science-educational pharmacy format in Russia. The first Russian Фитотека opened at the 'Island of Dreams' shopping center in Moscow in September 2020. Unipharm provides the pharmacy retail presence and professional pharmacist consultations; Bionorica provides the concept, training, and product range. There are 55 Фитотеки in Russia as of 2020.
• Leopold Franzens University of InnsbruckcoreStrategic or Co-development Partner · 1 January 2017In 2017, the M. Popp Institute was founded at Innsbruck University as part of the Phytovalley® Tyrol initiative. The institute aims to position Innsbruck and the region as a center for modern scientific research on medicinal herbs. Research staff of approximately 20 scientists and students are jointly funded by the Tyrol state administration and Prof. Popp.
• 500+ Global Research Institutions (Universities, Clinics, Institutes)coreStrategic or Co-development PartnerBionorica operates a global research network comprising more than 500 leading institutes, clinics, and universities worldwide. Research collaborations span plant ingredient analysis, clinical trials, and R&D activities. Part of the Phytovalley® Tyrol initiative with Innsbruck University.
• Phytoneering Extracts Solutions GmbHcoreOEM/ Whitelabel/ Licensing PartnerWholly-owned Bionorica subsidiary manufacturing standardized plant extracts. Produces extracts at Neumarkt, Germany and Mallorca, Spain facilities. Sells extracts to other pharmaceutical manufacturers worldwide.
• Phytoneering Extracts Solutions S.L.coreOEM/ Whitelabel/ Licensing PartnerBionorica subsidiary based in Конселл, Mallorca. Uses new cultivation and processing techniques for medicinal plants under the Phytoneering philosophy. Climate and soil conditions on Mallorca are optimized for highest quality raw materials.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Dr. Willmar Schwabe GmbH & Co. KG: German family-owned phytopharmaceutical company and one of the world's largest plant-based medicine manufacturers (e.g., Tebonin, Crataegutt). Closest direct peer to Bionorica in product category, German heritage, OTC respiratory and circulatory positioning, and family-ownership structure.
• Biologische Heilmittel Heel GmbH: German manufacturer of plant-based and homeopathic medicines with global presence across respiratory, gynecology, and pain indications. Highly comparable to Bionorica in business model, German HQ, and physician-detail-led phytopharmaceutical portfolio.
• Engelhard Arzneimittel GmbH & Co. KG: German family-owned producer of plant-based OTC medicines (Prospan for coughs, Sinuc, Isla-Moos). Directly comparable mid-sized German phytopharma focused on respiratory and ENT, similar GTM through medical reps and pharmacy channels.
• Steigerwald Arzneimittelwerk GmbH: German plant-based pharma company (part of Bayer Consumer Health) producing Iberogast and other phytopharmaceuticals for gastrointestinal and related indications. Comparable in phytopharma heritage and HCP-driven distribution.
• A. Vogel AG: Swiss plant-based medicine manufacturer (Echinaforce, A.Vogel tinctures) with strong pharmacy distribution across Europe. Comparable as a mid-sized European player in evidence-based herbal OTC medicines with similar therapeutic-area coverage in respiratory and women's health.
• Cesra Arzneimittel GmbH & Co. KG: German mid-sized manufacturer of plant-based OTC medicines (e.g., Cefakliman, Venen-Tropfen). Comparable as a smaller German phytopharma peer with similar regulatory positioning and physician-targeted marketing.
• Kwizda Pharma GmbH: Austrian pharma company with phytopharmaceutical and OTC focus, including respiratory and women's health brands. Comparable as a mid-sized European plant-based pharma peer operating across similar therapeutic niches and pharmacy-retelivery models.

Broad incumbents

• Bayer AG (Consumer Health): Global pharma and consumer health giant with significant phytopharmaceutical and OTC portfolio (e.g., Iberogast via Steigerwald, Aspirin, Bepanthen). Broader incumbent competing in the same pharmacy channels and respiratory/pain OTC categories as Bionorica.
• Stada Arzneimittel AG: German generics and consumer health company with broad OTC portfolio including phytopharmaceuticals (e.g., Grippostad, Hoggar). Comparable as a German-headquartered competitor in OTC pharmacy channels, though broader and more generic-focused than Bionorica.

Regional players

• Pharmstandard JSC: Leading Russian pharmaceutical manufacturer with broad OTC and prescription portfolio including plant-based products. Comparable as the dominant Russian-market competitor to OOO Bionorica in respiratory and women's health OTC categories served through pharmacy chains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ooo bionorica